<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEXIUM - esomeprazole magnesium capsule, delayed release </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use NEXIUM safely and effectively. See full prescribing information for NEXIUM.NEXIUM (esomeprazole magnesium) Delayed-Release Capsules, for Oral Use NEXIUM (esomeprazole magnesium) For Delayed-Release Oral SuspensionInitial U.S. Approval: 1989 (omeprazole)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p><span><span class="Italics">Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></span></p>
<p><span>NEXIUM is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of NEXIUM may be considered.</span></p>
<p><span>In infants 1 month to less than 1 year, NEXIUM is indicated for short-term treatment (up to 6 weeks) of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> due to acid-mediated <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>.</span></p>
<p><span class="Italics">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></p>
<p>NEXIUM is indicated to maintain symptom resolution and healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. Controlled studies do not extend beyond 6 months.</p>
<p><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> </span></p>
<p>NEXIUM is indicated for short-term treatment (4 to 8 weeks) of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in adults and children 1 year or older. </p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>NEXIUM is indicated for the reduction in the occurrence of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> associated with continuous NSAID therapy in patients at risk for developing <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>. Controlled studies do not extend beyond 6 months.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Triple Therapy (NEXIUM plus amoxicillin and clarithromycin): NEXIUM, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or history of within the past 5 years) to eradicate <span class="Italics">H. pylori</span>. Eradication of <span class="Italics">H. pylori</span> has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1158841553901">Dosage and Administration (2)</a> and <a href="#williamsonbk1158778492663">Clinical Studies (14)</a></span>].</p>
<p>In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1158777874678">Clinical Pharmacology (12.4)</a> and the prescribing information for clarithromycin</span>].</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>NEXIUM is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>NEXIUM is supplied as delayed-release capsules for oral administration or in packets for preparation of delayed-release oral suspensions. The recommended dosages are outlined in Table 1. NEXIUM should be taken at least one hour before meals.</p>
<p> The duration of proton pump inhibitor administration should be based on available safety and efficacy data specific to the defined indication and dosing frequency, as described in the prescribing information, and individual patient medical needs. Proton pump inhibitor treatment should only be initiated and continued if the benefits outweigh the risks of treatment.</p>
<a name="_RefID0EEYAG"></a><table>
<caption><span>Table 1: Recommended Dosage Schedule of NEXIUM</span></caption>
<col span="1" width="71%">
<col span="1" width="19%">
<col span="1" width="25%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Indication</p></td>
<td><p class="First">Dose</p></td>
<td><p class="First">Frequency</p></td>
</tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</span></p></td></tr>
<tr>
<td><p class="First">Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></p></td>
<td><p class="First">20 mg or 40 mg</p></td>
<td><p class="First">Once Daily for 4 to 8 Weeks<a href="#footnote-1">*</a></p></td>
</tr>
<tr>
<td><p class="First">Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </p></td>
<td><p class="First">20 mg </p></td>
<td><p class="First">Once Daily<a href="#footnote-2">†</a></p></td>
</tr>
<tr>
<td><p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span></p></td>
<td><p class="First">20 mg</p></td>
<td><p class="First">Once Daily for 4 Weeks<a href="#footnote-3">‡</a></p></td>
</tr>
<tr><td>
<p class="First"><span class="Bold">Pediatric <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></span></p>
<p><span>12 to 17 Year Olds</span></p>
</td></tr>
<tr>
<td>
<p class="First"><span>Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></span></p>
<p><span>Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></span></p>
</td>
<td>
<p class="First"><span>20 mg or 40 mg</span></p>
<p><span>20 mg</span></p>
</td>
<td>
<p class="First"><span>Once Daily for 4 to 8 Weeks</span></p>
<p><span>Once Daily for 4 Weeks</span></p>
</td>
</tr>
<tr><td><p class="First"><span class="Bold">1 to 11 Year Olds</span><a href="#footnote-4">§</a></p></td></tr>
<tr>
<td><p class="First">Short-term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></p></td>
<td><p class="First">10 mg</p></td>
<td><p class="First">Once Daily for up to 8 Weeks</p></td>
</tr>
<tr><td><p class="First">Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></p></td></tr>
<tr>
<td><p class="First">   weight &lt; 20 kg  </p></td>
<td><p class="First">10 mg</p></td>
<td><p class="First">Once Daily for 8 Weeks</p></td>
</tr>
<tr>
<td><p class="First">weight ≥ 20 kg</p></td>
<td><p class="First">10 mg or 20 mg</p></td>
<td><p class="First">Once Daily for 8 Weeks</p></td>
</tr>
<tr>
<td><p class="First"><span><span class="Bold">1 month to &lt; 1 year old</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive esophagitis</span> due to acid-mediated <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span>weight 3 kg to 5 kg</span></p></td>
<td><p class="First"><span>2.5 mg</span></p></td>
<td><p class="First"><span>Once Daily for up to 6 Weeks</span></p></td>
</tr>
<tr>
<td><p class="First"><span>weight &gt; 5 kg to 7.5 kg</span></p></td>
<td><p class="First"><span>5 mg</span></p></td>
<td><p class="First"><span>Once Daily for up to 6 Weeks</span></p></td>
</tr>
<tr>
<td><p class="First"><span>weight &gt;7.5 kg to 12 kg</span></p></td>
<td><p class="First"><span>10 mg</span></p></td>
<td><p class="First"><span>Once Daily for up to 6 Weeks</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Risk Reduction of NSAID-Associated <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></span></p></td>
<td><p class="First">20 mg or 40 mg</p></td>
<td><p class="First">Once Daily for up to 6 months<a href="#footnote-2" class="Sup">2</a></p></td>
</tr>
<tr><td><p class="First"><span class="Bold"><span class="Italics">H. pylori </span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence</span></p></td></tr>
<tr>
<td><p class="First"><span class="Italics">Triple Therapy:</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">NEXIUM</p></td>
<td><p class="First">40 mg</p></td>
<td><p class="First">Once Daily for 10 Days</p></td>
</tr>
<tr>
<td><p class="First">Amoxicillin</p></td>
<td><p class="First">1000 mg</p></td>
<td><p class="First">Twice Daily for 10 Days</p></td>
</tr>
<tr>
<td><p class="First">Clarithromycin</p></td>
<td><p class="First">500 mg</p></td>
<td><p class="First">Twice Daily for 10 Days</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome</span></p></td>
<td><p class="First">40 mg<a href="#footnote-5">¶</a></p></td>
<td><p class="First"><a href="#footnote-6">#</a> Twice Daily</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>Please refer to amoxicillin and clarithromycin prescribing information for Contraindications, Warnings, and dosing in elderly and renally-impaired patients.</p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>In patients with mild to moderate liver impairment (Child Pugh Classes A and B), no dosage adjustment is necessary. For patients with severe liver impairment (Child Pugh Class C), a dose of 20 mg of NEXIUM should not be exceeded [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1185372821742">Clinical Pharmacology (12.3)</a></span>].</p>
<p>Directions for use specific to the route and available methods of administration for each of these dosage forms are presented in Table 2.</p>
<p><span class="Bold">Table 2: Administration Options</span></p>
<table>
<col span="1" width="20%">
<col span="1" width="18%">
<col span="1" width="77%">
<tbody class="Headless">
<tr class="First"><td>
<p class="First"><span class="Bold">Administration Options </span></p>
<p><span class="Bold">(See text following table for additional instructions.)</span></p>
</td></tr>
<tr>
<td><p class="First"><span class="Bold">Dosage Form</span></p></td>
<td><p class="First"><span class="Bold">Route</span></p></td>
<td><p class="First"><span class="Bold">Options</span></p></td>
</tr>
<tr>
<td><p class="First">Delayed-Release Capsules</p></td>
<td><p class="First">Oral</p></td>
<td>
<p class="First">Capsule can be swallowed whole.</p>
<p>-or-</p>
<p> Capsule can be opened and mixed with applesauce.</p>
</td>
</tr>
<tr>
<td><p class="First">Delayed-Release Capsules</p></td>
<td><p class="First">Nasogastric Tube</p></td>
<td><p class="First">Capsule can be opened and the intact granules emptied into a syringe and delivered through the nasogastric tube.</p></td>
</tr>
<tr>
<td><p class="First">For Delayed-Release Oral Suspension</p></td>
<td><p class="First">Oral </p></td>
<td>
<p class="First">For the 2.5 mg and 5 mg strengths, mix the contents of packet with 5 mL of water, leave 2 to 3 minutes to thicken, stir and drink within 30 minutes. </p>
<p>For the 10 mg, 20 mg and 40 mg strengths, mix contents of packet with 15 mL of water, and follow the instructions above.</p>
</td>
</tr>
<tr class="Last">
<td><p class="First">For Delayed-Release Oral Suspension</p></td>
<td><p class="First">Nasogastric or Gastric Tube</p></td>
<td>
<p class="First">For the 2.5 mg and 5 mg strengths, add 5 mL of water to a syringe and then add contents of packet. Shake the syringe; leave 2 to 3 minutes to thicken. Shake the syringe and inject through the nasogastric or gastric tube within 30 minutes. </p>
<p>For the 10 mg, 20 mg and 40 mg strengths, add 15 mL of water, and follow the instructions above.</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Underline">NEXIUM Delayed-Release Capsules</span></p>
<p>NEXIUM Delayed-Release Capsules should be swallowed whole.</p>
<p>Alternatively, for patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the NEXIUM Delayed-Release Capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately: do not store for future use. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The granules should not be chewed or crushed. If the granules/applesauce mixture is not used in its entirety, the remaining mixture should be discarded immediately.</p>
<p>For patients who have a nasogastric tube in place, NEXIUM Delayed-Release Capsules can be opened and the intact granules emptied into a 60 mL catheter tipped syringe and mixed with 50 mL of water. It is important to only use a catheter tipped syringe when administering NEXIUM through a nasogastric tube. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a nasogastric tube and deliver the contents of the syringe through the nasogastric tube into the stomach. After administering the granules, the nasogastric tube should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with additional water. Do not administer the granules if they have dissolved or disintegrated. </p>
<p>The mixture must be used immediately after preparation.</p>
<p><span class="Underline">NEXIUM For Delayed-Release Oral Suspension </span></p>
<p>NEXIUM For Delayed-Release Oral Suspension should be administered as follows:</p>•Empty the contents of a 2.5 mg or 5 mg packet into a container containing 5 mL of water. For the 10 mg, 20 mg, and 40 mg strengths, the contents of a packet should be emptied into a container containing 15 mL of water.•Stir.•Leave 2 to 3 minutes to thicken.  •Stir and drink within 30 minutes.•If any medicine remains after drinking, add more water, stir, and drink immediately.•In cases where there is a need to use two packets, they may be mixed in a similar way by adding twice the required amount of water or follow the mixing instructions provided by your pharmacist or doctor.<p>For patients who have a nasogastric or gastric tube in place, NEXIUM For Delayed-Release Oral Suspension can be administered as follows:</p>•Add 5 mL of water to a catheter tipped syringe and then add the contents of a 2.5 mg or 5 mg NEXIUM packet. For the 10 mg, 20 mg, and 40 mg strengths, the volume of water in the syringe should be 15 mL. It is important to only use a catheter tipped syringe when administering NEXIUM through a nasogastric tube or gastric tube.•Immediately shake the syringe and leave 2 to 3 minutes to thicken.•Shake the syringe and inject through the nasogastric or gastric tube, French size 6 or larger, into the stomach within 30 minutes.•Refill the syringe with an equal amount of water (5 mL or 15 mL).•Shake and flush any remaining contents from the nasogastric or gastric tube into the stomach.<p>
 
</p>
<br><p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>[</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>Controlled studies did not extend beyond six months.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>Doses over 1 mg/kg/day have not been studied.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">5</a></dt>
<dd>The dosage of NEXIUM in patients with pathological hypersecretory conditions varies with the individual patient. Dosage regimens should be adjusted to individual patient needs.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">6</a></dt>
<dd>Doses up to 240 mg daily have been administered [</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>NEXIUM Delayed-Release Capsules, 20 mg - opaque, hard gelatin, amethyst colored capsules with two radial bars in yellow on the cap and NEXIUM 20 mg in yellow on the body.</p>
<p>NEXIUM Delayed-Release Capsules, 40 mg - opaque, hard gelatin, amethyst colored capsules with three radial bars in yellow on the cap and NEXIUM 40 mg in yellow on the body.</p>
<p>NEXIUM For Delayed-Release Oral Suspension, 2.5 mg, 5 mg, 10 mg, 20 mg or 40 mg - unit dose packet containing a fine yellow powder, consisting of white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> brownish esomeprazole granules and <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow inactive granules.</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>NEXIUM is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to proton pump inhibitors. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, e.g., <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, have been reported with NEXIUM use.</p>
<p>For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with NEXIUM, refer to the CONTRAINDICATIONS section of their package inserts.</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>Symptomatic response to therapy with NEXIUM does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which esomeprazole is an enantiomer.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span>Published observational studies suggest that PPI therapy like NEXIUM may be associated with an increased risk of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, especially in hospitalized patients.  This diagnosis should be considered for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve [<span class="Italics">see </span></span><span class="Italics"><a href="#ID_cc066777-b02d-4939-ce97-1f292bf730b1">Adverse Reactions (6.2)</a></span><span>]. </span></p>
<p><span>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. </span></p>
<p><span><span class="Italics">Clostridium diffficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents.  For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with NEXIUM, refer to WARNINGS and PRECAUTIONS sections of those package inserts.</span></p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span>Avoid concomitant use of NEXIUM with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as esomeprazole that inhibit CYP2C19 activity. Concomitant use of clopidogrel with 40 mg esomeprazole reduces the pharmacological activity of clopidogrel.  When using NEXIUM consider alternative anti-platelet therapy.  [see </span><span class="Italics"><a href="#williamsonbk1310047508742">Drug Interactions (7.3)</a></span><span><span class="Italics">and </span></span><span class="Italics"><a href="#williamsonbk1185372821742">Pharmacokinetics (12.3)</a></span><span>]</span></p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> should be managed according to established treatment guidelines. [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1158841553901">Dosage and Administration (2)</a> and <a href="#ID_cc066777-b02d-4939-ce97-1f292bf730b1">Adverse Reactions (6.2)</a></span>]</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy.  Serious adverse events include <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.  In most patients, treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> required magnesium replacement and discontinuation of the PPI.</p>
<p>For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically. [<span class="Italics">See</span><span class="Italics"><a href="#ID_cc066777-b02d-4939-ce97-1f292bf730b1">Adverse Reactions (6.2)</a></span>]</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Drugs which induce CYP2C19 or CYP3A4 (such as St John’s Wort or rifampin) can substantially decrease esomeprazole concentrations. [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1310047508742">Drug Interactions (7.3)</a></span>] Avoid concomitant use of NEXIUM with St John’s Wort, or rifampin.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop esomeprazole treatment before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span>Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration a temporary withdrawal of the PPI may be considered in some patients. [<span class="Italics">see </span></span><span class="Italics"><a href="#williamsonbk1327936521605">Drug Interactions (7.7)</a></span><span>]</span></p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Adults</span></p>
<p>The safety of NEXIUM was evaluated in over 15,000 patients (aged 18 to 84 years) in clinical trials worldwide including over 8,500 patients in the United States and over 6,500 patients in Europe and Canada. Over 2,900 patients were treated in long-term studies for up to 6-12 months. In general, NEXIUM was well tolerated in both short and long-term clinical trials.</p>
<p>The safety in the treatment of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> was assessed in four randomized comparative clinical trials, which included 1,240 patients on NEXIUM 20 mg, 2,434 patients on NEXIUM 40 mg, and 3,008 patients on omeprazole 20 mg daily. The most frequently occurring adverse reactions (≥1%) in all three groups were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.5, 5, and 3.8, respectively) and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (no difference among the three groups). <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> occurred at similar rates among patients taking NEXIUM or omeprazole.</p>
<p>Additional adverse reactions that were reported as possibly or probably related to NEXIUM with an incidence &lt; 1% are listed below by body system:</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">substernal chest pain</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, flu-like disorder, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>; </p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; </p>
<p><span class="Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>; </p>
<p><span class="Italics">Gastrointestinal:</span> bowel irregularity, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation aggravated</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> GI, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="31610" conceptname="Disorder of esophagus">esophageal disorder</span>, frequent stools, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span>, GI symptoms not otherwise specified, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, mouth disorder, pharynx disorder, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, serum gastrin increased, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; </p>
<p><span class="Italics">Hearing:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; </p>
<p><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">anemia hypochromic</span>, cervical <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>,  <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>;</p>
<p><span class="Italics">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, SGPT increased; </p>
<p><span class="Italics">Metabolic/Nutritional:</span> <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, increased alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, vitamin B12 deficiency, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>; </p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis aggravated</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia syndrome</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span>; </p>
<p><span class="Italics">Nervous System/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, appetite increased, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression aggravated</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine aggravated</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>; </p>
<p><span class="Italics">Reproductive:</span> <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>; </p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma aggravated</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">larynx edema</span>,  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>; </p>
<p><span class="Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="200169" conceptname="Pruritus ani">pruritus ani</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">skin inflammation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; </p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>; </p>
<p><span class="Italics">Urogenital: </span> abnormal urine, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, micturition frequency, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>; </p>
<p><span class="Italics">Visual: </span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>.</p>
<p>The following potentially clinically significant laboratory changes in clinical trials, irrespective of relationship to NEXIUM, were reported in ≤ 1% of patients: increased creatinine, uric acid, total bilirubin, alkaline phosphatase, ALT, AST, hemoglobin, white blood cell count, platelets, serum gastrin, potassium, sodium, thyroxine and thyroid stimulating hormone [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1158843286000">Clinical Pharmacology (12)</a></span>]. Decreases were seen in hemoglobin, white blood cell count, platelets, potassium, sodium, and thyroxine.</p>
<p>Endoscopic findings that were reported as adverse reactions include: <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4268622" conceptname="Stricture of esophagus">esophageal stricture</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span>, <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, benign <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> or <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, Barrett’s esophagus, and <span class="product-label-link" type="condition" conceptid="44791183" conceptname="Pale mucous membrane">mucosal discoloration</span>.</p>
<p>The incidence of treatment-related adverse reactions during 6-month maintenance treatment was similar to placebo. There were no differences in types of related adverse reactions seen during maintenance treatment up to 12 months compared to short-term treatment.</p>
<p>Two placebo-controlled studies were conducted in 710 patients for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>.  The most common adverse reactions that were reported as possibly or probably related to NEXIUM were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4.3%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3.8%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3.8%).</p>
<p><span class="Bold">Pediatrics</span></p>
<p>The safety of NEXIUM was evaluated in 316 pediatric and adolescent patients aged 1 to 17 years in four clinical trials for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1185473675741">Clinical Studies (14.2)</a></span>]. In 109 pediatric patients aged 1 to 11 years, the most frequently reported (at least 1%) treatment-related adverse reactions in these patients were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.8%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (1.9%) and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1.9%). In 149 pediatric patients aged 12 to 17 years the most frequently reported (at least 2%) treatment-related adverse reactions in these patients were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (8.1%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2.7%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%).</p>
<p>The safety of NEXIUM was evaluated in 167 pediatric patients from birth to &lt;1 year of age in three clinical trials. [<span class="Italics">See </span><span class="Italics"><a href="#williamsonbk1185378883110">Clinical Studies (14.3)</a></span>] In a study that included 26 pediatric patients aged birth to 1 month there were no treatment related adverse reactions. In a study that included 43 pediatric patients age 1 to 11 months, inclusive the most frequently reported (at least 5%) adverse reactions, irrespective of causality, were <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In a study that included 98 pediatric patients, age 1 to 11 months, inclusive exposed to esomeprazole for up to 6 weeks (including 39 patients randomized to the withdrawal phase), there were 4 treatment-related adverse reactions: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1%), <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span> (1%), <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span> (1%), and increased ALT (1%).</p>
<p>No new safety concerns were identified in pediatric patients.</p>
<p><span class="Bold">Combination Treatment with Amoxicillin and Clarithromycin </span></p>
<p>In clinical trials using combination therapy with NEXIUM plus amoxicillin and clarithromycin, no additional adverse reactions specific to these drug combinations were observed. Adverse reactions that occurred were limited to those observed when using NEXIUM, amoxicillin, or clarithromycin alone. </p>
<p>The most frequently reported drug-related adverse reactions for patients who received triple therapy for 10 days were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (9.2%), <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (6.6%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3.7%). No treatment-emergent adverse reactions were observed at higher rates with triple therapy than were observed with NEXIUM alone. </p>
<p>For more information on adverse reactions with amoxicillin or clarithromycin, refer to their package inserts, Adverse Reactions sections. </p>
<p>In clinical trials using combination therapy with NEXIUM plus amoxicillin and clarithromycin, no additional increased laboratory abnormalities particular to these drug combinations were observed. </p>
<p>For more information on laboratory changes with amoxicillin or clarithromycin, refer to their package inserts, Adverse Reactions section.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>The following adverse reactions have been identified during post-approval use of NEXIUM. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reports are listed below by body system:</p>
<p><span class="Italics">Blood And Lymphatic: </span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>;</p>
<p><span class="Italics">Eye: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>;</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>; microscopic <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span></p>
<p><span class="Italics">Hepatobiliary:</span> <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; </p>
<p><span class="Italics">Immune System:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>; </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="193133" conceptname="Gastrointestinal candidiasis">GI candidiasis</span>; <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>;</p>
<p><span class="Italics">Metabolism and nutritional disorders:</span> <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span></p>
<p><span class="Italics">Musculoskeletal and Connective Tissue:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>;</p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>; </p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>; </p>
<p><span class="Italics">Renal and Urinary:</span> interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; </p>
<p><span class="Italics">Reproductive System and Breast:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>; </p>
<p><span class="Italics">Respiratory, Thoracic, and Mediastinal:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>; </p>
<p><span class="Italics">Skin and Subcutaneous Tissue:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (some fatal).</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>Concomitant use of atazanavir and nelfinavir with proton pump inhibitors is not recommended.  Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and may result in a loss of therapeutic effect and the development of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>.  Co-administration of saquinavir with proton pump inhibitors is expected to increase saquinavir concentrations, which may increase toxicity and require dose reduction.  </p>
<p>Omeprazole, of which esomeprazole is an enantiomer, has been reported to interact with some antiretroviral drugs.  The clinical importance and the mechanisms behind these interactions are not always known.  Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug.  Other possible interaction mechanisms are via CYP 2C19.    </p>
<p><span class="Italics">Reduced concentrations of atazanavir and nelfinavir </span></p>
<p>For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole.  Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, C<span class="Sub">max</span> by 37% and 89% and C<span class="Sub">min</span> by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hr before atazanavir), AUC was decreased by 94%, C<span class="Sub">max</span> by 96%, and C<span class="Sub">min</span> by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended.    </p>
<p><span class="Italics">Increased concentrations of saquinavir</span></p>
<p>For other antiretroviral drugs, such as saquinavir, elevated  serum levels have been reported, with an increase in AUC by 82%, in C<span class="Sub">max</span> by 75%, and in C<span class="Sub">min</span> by 106%, following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15.  Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with NEXIUM.  Dose reduction of saquinavir should be considered from the safety perspective for individual patients.    </p>
<p>There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Esomeprazole inhibits gastric acid secretion.  Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability.  Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, and erlotinib can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole.  Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects).  Esomeprazole is an enantiomer of omeprazole.  Coadministration of digoxin with esomeprazole is expected to increase the systemic exposure of digoxin. Therefore, patients may need to be monitored when digoxin is taken concomitantly with esomeprazole.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Esomeprazole is extensively metabolized in the liver by CYP 2C19 and CYP 3A4.  <span class="Italics"> In vitro</span> and <span class="Italics">in vivo</span> studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1, and 3A4. No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected.  Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin, or amoxicillin.   </p>
<p>However, post-marketing reports of changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> measures have been received among patients on concomitant warfarin and esomeprazole therapy. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.  </p>
<p>Esomeprazole may potentially interfere with CYP 2C19, the major esomeprazole metabolizing enzyme.  Coadministration of esomeprazole 30 mg and diazepam, a CYP 2C19 substrate, resulted in a 45% decrease in clearance of diazepam.  </p>
<p>Clopidogrel</p>
<p>Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of esomeprazole 40 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant administration of NEXIUM with clopidogrel. When using NEXIUM, consider use of alternative anti-platelet therapy [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1185372821742">Pharmaokinetics (12.3</a>)</span>].</p>
<p>Omeprazole acts as an inhibitor of CYP 2C19. Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased C<span class="Sub">max</span> and AUC of cilostazol by 18% and 26% respectively. C<span class="Sub">max</span> and AUC of one of its active metabolites, 3,4-dihydrocilostazol, which has 4-7 times the activity of cilostazol, were increased by 29% and 69% respectively. Co-administration of cilostazol with esomeprazole is expected to increase concentrations of cilostazol and its above mentioned active metabolite. Therefore a dose reduction of cilostazol from 100 mg twice daily to 50 mg twice daily should be considered.</p>
<p>Concomitant administration of esomeprazole and a combined inhibitor of CYP 2C19 and CYP 3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure. Dose adjustment of esomeprazole is not normally required. However, in patients with Zollinger-Ellison’s Syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered.</p>
<p>Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampin) may lead to decreased esomeprazole serum levels. Omeprazole, of which esomeprazole is an enantiomer, has been reported to interact with St. John’s wort an inducer of CYP3A4. In a cross-over study in 12 healthy male subjects, St John’s wort (300 mg three times daily for 14 days) significantly decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (C<span class="Sub">max</span> and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (C<span class="Sub">max</span> and AUC decreased by 49.6 % and 43.9%, respectively). Avoid concomitant use of St. John’s Wort or rifampin with NEXIUM.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Drug-induced decrease in gastric acidity results in enterochromaffin-like cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and increased Chromogranin A levels which may interfere with investigations for neuroendocrine tumors. [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1310048381585">Warnings and Precautions (5.7)</a> and <a href="#williamsonbk1310048423179">Clinical Pharmacology (12.2)</a></span>]</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Concomitant administration of esomeprazole and tacrolimus may increase the serum levels of tacrolimus.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1158777874678">Clinical Pharmacology (12.4)</a></span>].</p>
<p>Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [<span class="Italics">see</span><span class="Italics"> Warnings and Precautions in prescribing information for clarithromycin</span>].  Because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [<span class="Italics">see</span><span class="Italics"> Contraindications in prescribing information for clarithromycin</span>].</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted [<span class="Italics">see</span><span class="Italics"></span><span class="Italics"><a href="#ID_fc3fd2b4-f3fe-4bc2-82a2-d89dfd30eec8">Warnings and Precautions (5.8)</a></span>].</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p><span class="Italics">Pregnancy Category B </span></p>
<p>Reproductive studies in rats and rabbits with NEXIUM (esomeprazole) and multiple cohort studies in pregnant women with omeprazole use during the first trimester do not show an increased risk of congenital anomalies or adverse pregnancy outcomes. There are, however, no adequate and well controlled studies of NEXIUM use in pregnancy. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. </p>
<p>Esomeprazole is the s-isomer of omeprazole. In four population-based cohort studies that included 1226 women exposed during the first trimester of pregnancy to omeprazole there was no increased risk of congenital anomalies. </p>
<p>Reproductive studies with esomeprazole have been performed in rats at doses up to 57 times the human dose and in rabbits at doses up to 35 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus. [<span class="Italics">See</span><span class="Italics"><a href="#rowellsl1309364337994">Animal Toxicology and/or Pharmacology (13.2)</a></span>]</p>
<p>Reproductive studies conducted with omeprazole on rats at oral doses up to 56 times the human dose and in rabbits at doses up to 56 times the human dose did not show any evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. In pregnant rabbits, omeprazole at doses about 5.5 to 56 times the human dose produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy loss. In rats treated with omeprazole at doses about 5.6 to 56 times the human dose, dose-related embryo/fetal toxicity and postnatal developmental toxicity occurred in offspring.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Omeprazole concentrations have been measured in breast milk of one woman taking omeprazole 20 mg per day.  However, the excretion of esomeprazole in milk has not been studied.  It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for NEXIUM in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>The safety and effectiveness of NEXIUM have been established in pediatric patients 1 to 17 years of age for short-term treatment (up to eight weeks) of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. The safety and effectiveness of NEXIUM have been established in pediatric patients 1 month to less than 1 year for short-term treatment (up to 6 weeks) of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> due to acid-mediated <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. However, the safety and effectiveness of NEXIUM have not been established in patients less than 1 month of age.</p>
<p><span class="Italics">1 to 17 years of age </span></p>
<p>Use of NEXIUM in pediatric and adolescent patients 1 to 17 years of age for short-term treatment (up to eight weeks) of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> is supported by extrapolation of results from adequate and well-controlled studies for adults and safety and pharmacokinetic studies performed in pediatric and adolescent patients [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1185372821742">Clinical Pharmacology (12.3)</a>, <a href="#williamsonbk1158841553901">Dosage and Administration (2)</a>, <a href="#williamsonbk1185474323706">Adverse Reactions (6.1)</a>, and </span><span class="Italics"><a href="#williamsonbk1185378883110">Clinical Studies (14.3)</a></span>].  The safety and effectiveness of NEXIUM for other pediatric uses have not been established.   </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive esophagitis</span> due to acid-mediated <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in infants 1 month to less than one year of age</span></p>
<p>Use of NEXIUM in pediatric patients 1 month to less than 1 year of age for treatment (up to 6 weeks) of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> due to acid-mediated <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> is supported by extrapolation of results from adequate and well-controlled studies for adults and safety, pharmacokinetic, and pharmacodynamic studies performed in pediatric patients [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1185372821742">Clinical Pharmacology (12.3)</a>, <a href="#williamsonbk1158841553901">Dosage and Administration (2)</a>, <a href="#williamsonbk1185474323706">Adverse Reactions (6.1)</a>, and <a href="#williamsonbk1185378883110">Clinical Studies, (14.3)</a></span>].</p>
<p><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in infants 1 month to less than one year of age</span></p>
<p>There was no statistically significant difference between NEXIUM and placebo in the rate of discontinuation due to symptom worsening in a multicenter, randomized, double-blind, controlled, treatment-withdrawal study of 98 patients ages 1 to 11 months, inclusive. Patients were enrolled if they had either a clinical diagnosis of suspected <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, or endoscopically proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. Twenty of 98 enrolled patients underwent endoscopy, and 6 patients were found to have <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> on endoscopy at baseline. All patients received NEXIUM Delayed-Release Oral Suspension once daily during a two-week, open-label phase of the study. </p>
<p>There were 80 patients who attained a pre-specified level of symptom improvement and who entered the double-blind phase, in which they were randomized in equal proportions to receive NEXIUM or placebo for the next four weeks.  Efficacy was assessed by observing the time from randomization to study discontinuation due to symptom worsening during the four-week, treatment-withdrawal phase. </p>
<p>The following pharmacokinetic and pharmacodynamic information was obtained in pediatric patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> aged birth to less than one year of age.  In infants (1 to 11 months old, inclusive) given NEXIUM 1 mg/kg once daily, the percent time with intragastric pH &gt; 4 increased from 29% at baseline to 69% on Day 7, which is similar to the pharmacodynamic effect in adults [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1310048423179">Clinical Pharmacology (12.2)</a></span>]. Apparent clearance (CL/F) increases with age in pediatric patients from birth to 2 years of age. </p>
<p><span class="Italics">Neonates 0 to 1 month of age </span></p>
<p>Following administration of oral NEXIUM in neonates the geometric mean (range) for the apparent clearance (CL/F) was 0.55 L/h/kg (0.25-1.6 L/h/kg). </p>
<p>The safety and effectiveness of NEXIUM in neonates have not been established.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Of the total number of patients who received NEXIUM in clinical trials, 1459 were 65 to 74 years of age and 354 patients were ≥ 75 years of age.</p>
<p>No overall differences in safety and efficacy were observed between the elderly and younger individuals, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>A single oral dose of esomeprazole at 510 mg/kg (about 103 times the human dose on a body surface area basis), was lethal to rats.  The major signs of acute toxicity were reduced motor activity, changes in respiratory frequency, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and intermittent <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span>.</p>
<p>The symptoms described in connection with deliberate NEXIUM <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (limited experience of doses in excess of 240 mg/day) are transient. Single doses of 80 mg of esomeprazole were uneventful. Reports of overdosage with omeprazole in humans may also be relevant. Doses ranged up to 2,400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and other adverse reactions similar to those seen in normal clinical experience (see omeprazole package insert - <span class="Italics"><a href="#ID_8233eed3-e9c2-4929-c884-50bc83a979b8">Adverse Reactions</a></span>). No specific antidote for esomeprazole is known. Since esomeprazole is extensively protein bound, it is not expected to be removed by dialysis. In the event of overdosage, treatment should be symptomatic and supportive.</p>
<p>As with the management of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the possibility of multiple drug ingestion should be considered.  For current information on treatment of any drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> contact a Poison Control Center at 1–800–222–1222.</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>DESCRIPTION</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>The active ingredient in the proton pump inhibitor NEXIUM<span class="Sup">®</span> (esomeprazole magnesium) Delayed-Release Capsules for oral administration and NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1<span class="Italics">H</span>-benzimidazole-1-yl) magnesium trihydrate. Esomeprazole is the S-isomer of omeprazole, which is a mixture of the S- and R- isomers. (Initial U.S. approval of esomeprazole magnesium: 2001). Its molecular formula is (C<span class="Sub">17</span>H<span class="Sub">18</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S)<span class="Sub">2</span>Mg x 3 H<span class="Sub">2</span>O with molecular weight of 767.2 as a trihydrate and 713.1 on an anhydrous basis. The structural formula is:</p>
<p>Figure 1</p>
<div class="Figure"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b533b80b-2e68-4c5c-aaba-159d96a1b2f0&amp;name=MM1.jpg"></div>
<p>The magnesium salt is a white to slightly colored crystalline powder. It contains 3 moles of water of solvation and is slightly soluble in water. The stability of esomeprazole magnesium is a function of pH; it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions.  At pH 6.8 (buffer), the half-life of the magnesium salt is about 19 hours at 25°C and about 8 hours at 37°C.</p>
<p>NEXIUM is supplied in delayed-release capsules and in packets for a delayed-release oral suspension. Each delayed-release capsule contains 20 mg, or 40 mg of esomeprazole (present as 22.3 mg, or 44.5 mg esomeprazole magnesium trihydrate) in the form of enteric-coated granules with the following inactive ingredients: glyceryl monostearate 40-55, hydroxypropyl cellulose, hypromellose, magnesium stearate, methacrylic acid copolymer type C, polysorbate 80, sugar spheres, talc, and triethyl citrate. The capsule shells have the following inactive ingredients:  gelatin, FD&amp;C Blue #1, FD&amp;C Red #40, D&amp;C Red #28, titanium dioxide, shellac, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, sodium hydroxide, polyvinyl pyrrolidone, and D&amp;C Yellow #10.</p>
<p>Each packet of NEXIUM For Delayed-Release Oral Suspension contains 2.5 mg, 5 mg, 10 mg, 20 mg, or 40 mg of esomeprazole, in the form of the same enteric-coated granules used in NEXIUM Delayed-Release Capsules, and also inactive granules. The inactive granules are composed of the following ingredients: dextrose, xanthan gum, crospovidone, citric acid, iron oxide, and hydroxypropyl cellulose. The esomeprazole granules and inactive granules are constituted with water to form a suspension and are given by oral, nasogastric, or gastric administration.</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<span class="Sup">+</span>/K<span class="Sup">+</span>-ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity.  This effect is dose-related up to a daily dose of 20 to 40 mg and leads to inhibition of gastric acid secretion.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="Italics">Antisecretory Activity</span></p>
<p>The effect of NEXIUM on intragastric pH was determined in patients with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> in two separate studies.  In the first study of 36 patients, NEXIUM 40 mg and 20 mg capsules were administered over 5 days. The results are shown in the Table 3:</p>
<table>
<caption><span>Table 3: Effect on Intragastric pH on Day 5 (N=36)</span></caption>
<col span="1" width="32%">
<col span="1" width="11%">
<col span="1" width="11%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Parameter</p></td>
<td>
<p class="First">NEXIUM</p>
<p>40 mg</p>
</td>
<td>
<p class="First">NEXIUM</p>
<p>20 mg  </p>
</td>
</tr>
<tr>
<td><p class="First">% Time Gastric  pH &gt;4<a href="#footnote-1">*</a>(Hours)</p></td>
<td>
<p class="First">70%<a href="#footnote-2">†</a></p>
<p>(16.8 h)</p>
</td>
<td>
<p class="First">53%</p>
<p>(12.7 h)</p>
</td>
</tr>
<tr>
<td><p class="First"> Coefficient of  variation</p></td>
<td><p class="First">26%</p></td>
<td><p class="First">37%</p></td>
</tr>
<tr>
<td><p class="First">Median 24 Hour pH</p></td>
<td><p class="First">4.9<a href="#footnote-8" class="Sup">8</a></p></td>
<td><p class="First">4.1</p></td>
</tr>
<tr>
<td><p class="First">Coefficient of  variation</p></td>
<td><p class="First">16%</p></td>
<td><p class="First">27%</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>In a second study, the effect on intragastric pH of NEXIUM 40 mg administered once daily over a five day period was similar to the first study, (% time with pH &gt; 4 was 68% or 16.3 hours).</p>
<p><span class="Italics">Serum Gastrin Effects </span></p>
<p>The effect of NEXIUM on serum gastrin concentrations was evaluated in approximately 2,700 patients in clinical trials up to 8 weeks and in over 1,300 patients for up to 6 to 12 months. The mean fasting gastrin level increased in a dose-related manner. This increase reached a plateau within two to three months of therapy and returned to baseline levels within four weeks after discontinuation of therapy.</p>
<p>Increased gastrin causes enterochromaffin-like cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and increased serum Chromogranin A (CgA) levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors.</p>
<p><span class="Italics">Enterochromaffin-like (ECL) Cell Effects </span></p>
<p>In 24-month carcinogenicity studies of omeprazole in rats, a dose-related significant occurrence of gastric ECL cell <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">carcinoid tumors</span> and ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was observed in both male and female animals [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1158778438991">Nonclinical Toxicology (13.1)</a></span>].  <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">Carcinoid tumors</span> have also been observed in rats subjected to fundectomy or long-term treatment with other proton pump inhibitors or high doses of H<span class="Sub">2</span>-receptor antagonists.</p>
<p>Human gastric biopsy specimens have been obtained from more than 3,000 patients treated with omeprazole in long-term clinical trials. The incidence of ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in these studies increased with time; however, no case of ECL cell carcinoids, <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span>, or neoplasia has been found in these patients. </p>
<p>In over 1,000 patients treated with NEXIUM (10, 20 or 40 mg/day) up to 6 to 12 months, the prevalence of ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> increased with time and dose. No patient developed ECL cell carcinoids, <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span>, or neoplasia in the gastric mucosa.</p>
<p><span class="Italics">Endocrine Effects</span></p>
<p>NEXIUM had no effect on thyroid function when given in oral doses of 20 or 40 mg for 4 weeks. Other effects of NEXIUM on the endocrine system were assessed using omeprazole studies.  Omeprazole given in oral doses of 30 or 40 mg for 2 to 4 weeks had no effect on carbohydrate metabolism, circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin, or secretin.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="Italics">Absorption</span></p>
<p>NEXIUM Delayed-Release Capsules and NEXIUM For Delayed-Release Oral Suspension contain a bioequivalent enteric-coated granule formulation of esomeprazole magnesium. Bioequivalency is based on a single dose (40 mg) study in 94 healthy male and female volunteers under fasting condition. After oral administration peak plasma levels (C<span class="Sub">max</span>) occur at approximately 1.5 hours (T<span class="Sub">max</span>). The C<span class="Sub">max </span> increases proportionally when the dose is increased, and there is a three-fold increase in the area under the plasma concentration-time curve (AUC) from 20 to 40 mg. At repeated once-daily dosing with 40 mg, the systemic bioavailability is approximately 90% compared to 64% after a single dose of 40 mg. The mean exposure (AUC) to esomeprazole increases from 4.32 µmol*hr/L on Day 1 to 11.2 µmol*hr/L on Day 5 after 40 mg once daily dosing.</p>
<p>The AUC after administration of a single 40 mg dose of NEXIUM is decreased by 43% to 53% after food intake compared to fasting conditions.  NEXIUM should be taken at least one hour before meals.</p>
<p>The pharmacokinetic profile of NEXIUM was determined in 36 patients with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> following repeated once daily administration of 20 mg and 40 mg capsules of NEXIUM over a period of five days. The results are shown in the Table 4:</p>
<table>
<caption><span>Table 4:  Pharmacokinetic Parameters of NEXIUM on Day 5 Following Oral Dosing for 5 Days</span></caption>
<col span="1" width="20%">
<col span="1" width="14%">
<col span="1" width="13%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Parameter <a href="#footnote-1">*</a> (CV)</p></td>
<td>
<p class="First">NEXIUM </p>
<p>40 mg  </p>
</td>
<td>
<p class="First">NEXIUM </p>
<p>20 mg  </p>
</td>
</tr>
<tr>
<td><p class="First">AUC (μmol*h/L)</p></td>
<td><p class="First">12.6 (42%)</p></td>
<td><p class="First">4.2 (59%)</p></td>
</tr>
<tr>
<td><p class="First">C<span class="Sub">max</span> (μmol/L)</p></td>
<td><p class="First">4.7 (37%)</p></td>
<td><p class="First">2.1 (45%)</p></td>
</tr>
<tr>
<td><p class="First">T<span class="Sub">max</span> (h)</p></td>
<td><p class="First">1.6</p></td>
<td><p class="First">1.6</p></td>
</tr>
<tr>
<td><p class="First">t<span class="Sub">1/2</span> (h)</p></td>
<td><p class="First">1.5</p></td>
<td><p class="First">1.2</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><span class="Italics">Distribution</span></p>
<p>Esomeprazole is 97% bound to plasma proteins.  Plasma protein binding is constant over the concentration range of 2 to 20 μmol/L. The apparent volume of distribution at steady state in healthy volunteers is approximately 16 L.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Esomeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system. The metabolites of esomeprazole lack antisecretory activity. The major part of esomeprazole’s metabolism is dependent upon the CYP 2C19 isoenzyme, which forms the hydroxy and desmethyl metabolites.  The remaining amount is dependent on CYP 3A4 which forms the sulphone metabolite. CYP 2C19 isoenzyme exhibits polymorphism in the metabolism of esomeprazole, since some 3% of Caucasians and 15 to 20% of Asians lack CYP 2C19 and are termed Poor Metabolizers. At steady state, the ratio of AUC in Poor Metabolizers to AUC in the rest of the population (Extensive Metabolizers) is approximately 2.</p>
<p>Following administration of equimolar doses, the S- and R-isomers are metabolized differently by the liver, resulting in higher plasma levels of the S- than of the R-isomer.</p>
<p><span class="Italics">Excretion</span></p>
<p>The plasma elimination half-life of esomeprazole is approximately 1 to 1.5 hours. Less than 1% of parent drug is excreted in the urine.  Approximately 80% of an oral dose of esomeprazole is excreted as inactive metabolites in the urine, and the remainder is found as inactive metabolites in the feces. </p>
<p><span class="Italics">Pharmacokinetics: Combination Therapy with Antimicrobials</span></p>
<p>Esomeprazole magnesium 40 mg once daily was given in combination with clarithromycin 500 mg twice daily and amoxicillin 1000 mg twice daily for 7 days to 17 healthy male and female subjects. The mean steady state AUC and C<span class="Sub">max</span> of esomeprazole increased by 70% and 18%, respectively during triple combination therapy compared to treatment with esomeprazole alone. The observed increase in esomeprazole exposure during co-administration with clarithromycin and amoxicillin is not expected to produce significant safety concerns.</p>
<p>The pharmacokinetic parameters for clarithromycin and amoxicillin were similar during triple combination therapy and administration of each drug alone. However, the mean AUC and C<span class="Sub">max</span> for 14-hydroxyclarithromycin increased by 19% and 22%, respectively, during triple combination therapy compared to treatment with clarithromycin alone. This increase in exposure to 14-hydroxyclarithromycin is not considered to be clinically significant.</p>
<p><span class="Bold">Concomitant Use with Clopidogrel</span></p>
<p>Results from a crossover study in healthy subjects have shown a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg p.o. once daily) when co-administered for 30 days. Exposure to the active metabolite of clopidogrel was reduced by 35% to 40% over this time period. Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation was related to the change in the exposure to clopidogrel active metabolite.</p>
<p><span class="Bold">Special Populations </span></p>
<p><span class="Italics">Geriatric</span></p>
<p>The AUC and C<span class="Sub">max </span> values were slightly higher (25% and 18%, respectively) in the elderly as compared to younger subjects at steady state. Dosage adjustment based on age is not necessary.</p>
<p><span class="Italics">Pediatric (1 to 11 month of age)</span></p>
<p>The pharmacokinetic parameters following repeated dose administration of 1.0 mg/kg esomeprazole in 1 to 11 month old infants are summarized in Table 5.</p>
<a name="_RefID0EITAI"></a><table>
<caption><span>Table 5: Summary of PK parameters in 1 month to &lt; 1 year Olds with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Following 7/8 Days of Once-Daily Oral Esomeprazole Treatment</span></caption>
<col span="1" width="25%">
<col span="1" width="20%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First">1 month to &lt; 1 year</p></td>
</tr>
<tr>
<td><p class="First">Parameter</p></td>
<td><p class="First">1.0 mg/kg</p></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">AUC (μmol*h/L) (n=7)<a href="#footnote-2">*</a></p></td>
<td><p class="First">3.51</p></td>
</tr>
<tr>
<td><p class="First">C<span class="Sub">,max</span> (μmol/L) (n=15)<a href="#footnote-10" class="Sup">10</a></p></td>
<td><p class="First">0.87</p></td>
</tr>
<tr>
<td><p class="First">t<span class="Sub">½</span> (hours) (n=8)<a href="#footnote-10" class="Sup">10</a></p></td>
<td><p class="First">0.93</p></td>
</tr>
<tr>
<td><p class="First">t<span class="Sub">max</span> (hours) (n=15)<a href="#footnote-3">†</a></p></td>
<td><p class="First">3.0</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>Subsequent pharmacokinetic simulation analyses showed that a dosage regimen of 2.5 mg once-daily for pediatric patients with body weight 3-5 kg, 5.0 mg once-daily for &gt;5 to 7.5 kg and 10 mg once-daily for &gt;7.5 to 12 kg would achieve comparable steady-state plasma exposures (AUC) to that observed after 10 mg in 1 to 11 year olds, and 20 mg in 12 to 18 year-olds as well as adults.</p>
<p><span class="Italics">1 to 11 Years of Age</span></p>
<p>The pharmacokinetics of esomeprazole were studied in pediatric patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> aged 1 to 11 years. Following once daily dosing for 5 days, the total exposure (AUC) for the 10 mg dose in patients aged 6 to 11 years was similar to that seen with the 20 mg dose in adults and adolescents aged 12 to 17 years. The total exposure for the 10 mg dose in patients aged 1 to 5 years was approximately 30% higher than the 10 mg dose in patients aged 6 to 11 years. The total exposure for the 20 mg dose in patients aged 6 to 11 years was higher than that observed with the 20 mg dose in 12 to 17 year-olds and adults, but lower than that observed with the 40 mg dose in 12 to 17 year-olds and adults. See Table 6.</p>
<a name="_RefID0ESVAI"></a><table>
<caption><span>Table 6: Summary of PK Parameters in 1 to 11 Year Olds with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> following 5 Days of Once-Daily Oral Esomeprazole Treatment</span></caption>
<col span="1" width="19%">
<col span="1" width="18%">
<col span="1" width="14%">
<col span="1" width="14%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First"><span class="Bold">1 to 5 Year Olds</span></p></td>
<td><p class="First"><span class="Bold">6 to 11 Year Olds</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Parameter</span></p></td>
<td><p class="First"><span class="Bold">10 mg (N=8)</span></p></td>
<td><p class="First"><span class="Bold">10 mg (N=7)</span></p></td>
<td><p class="First"><span class="Bold">20 mg (N=6)</span></p></td>
</tr>
<tr>
<td><p class="First">AUC (μmol*h/L)<a href="#footnote-4">*</a></p></td>
<td><p class="First">4.83</p></td>
<td><p class="First">3.70</p></td>
<td><p class="First">6.28</p></td>
</tr>
<tr>
<td><p class="First">C<span class="Sub">max</span> (μmol/L)<a href="#footnote-12" class="Sup">12</a></p></td>
<td><p class="First">2.98</p></td>
<td><p class="First">1.77</p></td>
<td><p class="First">3.73</p></td>
</tr>
<tr>
<td><p class="First">t<span class="Sub">max</span> (h)<a href="#footnote-5">†</a></p></td>
<td><p class="First">1.44</p></td>
<td><p class="First">1.79</p></td>
<td><p class="First">1.75</p></td>
</tr>
<tr>
<td><p class="First">t<span class="Sub">½λz</span> (h)<a href="#footnote-12" class="Sup">12</a></p></td>
<td><p class="First">0.74</p></td>
<td><p class="First">0.88</p></td>
<td><p class="First">0.73</p></td>
</tr>
<tr>
<td><p class="First">Cl/F (L/h)<a href="#footnote-12" class="Sup">12</a></p></td>
<td><p class="First">5.99</p></td>
<td><p class="First">7.84</p></td>
<td><p class="First">9.22</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><span class="Italics">12 to 17 Years of Age</span></p>
<p>The pharmacokinetics of NEXIUM were studied in 28 adolescent patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> aged 12 to 17 years inclusive, in a single center study. Patients were randomized to receive NEXIUM 20 mg or 40 mg once daily for 8 days. Mean C<span class="Sub">max</span> and AUC values of esomeprazole were not affected by body weight or age; and more than dose-proportional increases in mean C<span class="Sub">max</span> and AUC values were observed between the two dose groups in the study. Overall, NEXIUM pharmacokinetics in adolescent patients aged 12 to 17 years were similar to those observed in adult patients with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. See Table 7.</p>
<a name="_RefID0EZ1AI"></a><table>
<caption><span>Table 7: Comparison of PK Parameters in 12 to 17 Year Olds with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and Adults with Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Following the Repeated Daily Oral Dose Administration of Esomeprazole<a href="#footnote-6">*</a></span></caption>
<col span="1" width="24%">
<col span="1" width="18%">
<col span="1" width="18%">
<col span="1" width="11%">
<col span="1" width="11%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First"><span class="Bold">12 to 17 Year Olds (N=28)</span></p></td>
<td><p class="First"><span class="Bold">Adults (N=36)</span></p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="Bold">20 mg </span></p></td>
<td><p class="First"><span class="Bold">40 mg </span></p></td>
<td><p class="First"><span class="Bold">20 mg</span></p></td>
<td><p class="First"><span class="Bold">40 mg</span></p></td>
</tr>
<tr>
<td><p class="First">AUC (μmol*h/L)</p></td>
<td><p class="First">3.65</p></td>
<td><p class="First">13.86</p></td>
<td><p class="First">4.2</p></td>
<td><p class="First">12.6</p></td>
</tr>
<tr>
<td><p class="First">C<span class="Sub">max</span> (μmol/L)</p></td>
<td><p class="First">1.45</p></td>
<td><p class="First">5.13</p></td>
<td><p class="First">2.1</p></td>
<td><p class="First">4.7</p></td>
</tr>
<tr>
<td><p class="First">t<span class="Sub">max</span> (h)</p></td>
<td><p class="First">2.00</p></td>
<td><p class="First">1.75</p></td>
<td><p class="First">1.6</p></td>
<td><p class="First">1.6</p></td>
</tr>
<tr>
<td><p class="First">t<span class="Sub">½λz</span> (h)</p></td>
<td><p class="First">0.82</p></td>
<td><p class="First">1.22</p></td>
<td><p class="First">1.2</p></td>
<td><p class="First">1.5</p></td>
</tr>
<tr><td><p class="First">Data presented are geometric means for AUC, C<span class="Sub">max </span> and t<span class="Sub">½λz</span>, and median value for t<span class="Sub">max</span>.</p></td></tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><span class="Italics">Gender</span></p>
<p>The AUC and C<span class="Sub">max </span> values were slightly higher (13%) in females than in males at steady state. Dosage adjustment based on gender is not necessary.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>The steady state pharmacokinetics of esomeprazole obtained after administration of 40 mg once daily to 4 patients each with mild (Child Pugh A), moderate (Child Pugh Class B), and severe (Child Pugh Class C) liver insufficiency were compared to those obtained in 36 male and female <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> patients with normal liver function. In patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, the AUCs were within the range that could be expected in patients with normal liver function. In patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> the AUCs were 2 to 3 times higher than in the patients with normal liver function. No dosage adjustment is recommended for patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child Pugh Classes A and B). However, in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child Pugh Class C) a dose of 20 mg once daily should not be exceeded [<span class="Italics">see</span><span class="Italics"><a href="#williamsonbk1158841553901">Dosage and Administration (2)</a></span>].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p>The pharmacokinetics of NEXIUM in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are not expected to be altered relative to healthy volunteers as less than 1% of esomeprazole is excreted unchanged in urine. </p>
<p><span class="Italics">Other pharmacokinetic observations </span></p>
<p>Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.    </p>
<p>Studies evaluating concomitant administration of esomeprazole and either naproxen (non-selective NSAID) or rofecoxib (COX-2 selective NSAID) did not identify any clinically relevant changes in the pharmacokinetic profiles of esomeprazole or these NSAIDs.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>NEXIUM, amoxicillin, and clarithromycin triple therapy has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Helicobacter pylori (H. pylori) in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [see <a href="#williamsonbk1158778506850">Indications and Usage (1)</a> and <a href="#williamsonbk1158778492663">Clinical Studies (14)</a>].</p>
<p><span class="Italics">Helicobacter pylori: </span>Susceptibility testing of <span class="Italics">H. pylori</span> isolates was performed for amoxicillin and clarithromycin using agar dilution methodology, and <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) were determined.</p>
<p><span class="Italics">Pretreatment Resistance: </span>Clarithromycin pretreatment resistance rate (MIC ≥ 1 mcg/mL) to <span class="Italics">H. pylori</span> was 15% (66/445) at baseline in all treatment groups combined.  A total of &gt; 99% (394/395) of patients had <span class="Italics">H. pylori </span> isolates that were considered to be susceptible (MIC ≤ 0.25 mcg/mL) to amoxicillin at baseline. One patient had a baseline <span class="Italics">H. pylori</span> isolate with an amoxicillin MIC = 0.5 mcg/mL. </p>
<p><span class="Italics">Clarithromycin Susceptibility Test Results and Clinical/Bacteriologic Outcomes:</span> The baseline <span class="Italics">H. pylori </span>clarithromycin susceptibility results and the <span class="Italics">H. pylori</span> eradication results at the Day 38 visit are shown in the Table 8:</p>
<a name="_RefID0ENCBI"></a><table>
<caption><span>Table 8: Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes<a href="#footnote-1">*</a> for Triple Therapy - (Esomeprazole magnesium 40 mg once daily/amoxicillin 1000 mg twice daily/clarithromycin 500 mg twice daily for 10 days)</span></caption>
<col span="1" width="37%">
<col span="1" width="22%">
<col span="1" width="9%">
<col span="1" width="7%">
<col span="1" width="6%">
<col span="1" width="8%">
<col span="1" width="15%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Clarithromycin  Pretreatment Results</p></td>
<td><p class="First"><span class="Italics">H. pylori</span> negative (Eradicated)</p></td>
<td>
<p class="First"><span class="Italics">H. pylori</span> positive</p>
<p>(Not Eradicated)</p>
<p>Post-treatment susceptibility results</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><p class="First">S <a href="#footnote-2">†</a></p></td>
<td><p class="First">I<a href="#footnote-16" class="Sup">16</a></p></td>
<td><p class="First">R <a href="#footnote-16" class="Sup">16</a></p></td>
<td><p class="First">No MIC</p></td>
</tr>
<tr>
<td><p class="First">Susceptible<a href="#footnote-16" class="Sup">16</a>  182</p></td>
<td><p class="First">162</p></td>
<td></td>
<td><p class="First">4</p></td>
<td><p class="First">0</p></td>
<td><p class="First">2</p></td>
<td><p class="First">14</p></td>
</tr>
<tr>
<td><p class="First">Intermediate<a href="#footnote-16" class="Sup">16</a>     1</p></td>
<td><p class="First">1</p></td>
<td></td>
<td><p class="First">0</p></td>
<td><p class="First">0</p></td>
<td><p class="First">0</p></td>
<td><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">Resistant<a href="#footnote-16" class="Sup">16</a>         29</p></td>
<td><p class="First">13</p></td>
<td></td>
<td><p class="First">1</p></td>
<td><p class="First">0</p></td>
<td><p class="First">13</p></td>
<td><p class="First">2</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>Patients not eradicated of <span class="Italics">H. pylori</span> following NEXIUM/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant <span class="Italics">H. pylori</span> isolates. Therefore, clarithromycin susceptibility testing should be done, when possible. Patients with clarithromycin resistant <span class="Italics">H. pylori</span> should not be re-treated with a clarithromycin-containing regimen. </p>
<p><span class="Italics">Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes:</span></p>
<p>In the NEXIUM/amoxicillin/clarithromycin clinical trials, 83% (176/212) of the patients in the NEXIUM/amoxicillin/clarithromycin treatment group who had pretreatment amoxicillin susceptible MICs (≤ 0.25 mcg/mL) were eradicated of <span class="Italics">H. pylori</span>, and 17% (36/212) were not eradicated of <span class="Italics">H. pylori</span>.  Of the 36 patients who were not eradicated of <span class="Italics">H. pylori</span> on triple therapy, 16 had no post-treatment susceptibility test results and 20 had post-treatment <span class="Italics">H. pylori</span> isolates with amoxicillin susceptible MICs. Fifteen of the patients who were not eradicated of <span class="Italics">H. pylori</span> on triple therapy also had post-treatment <span class="Italics">H. pylori</span> isolates with clarithromycin resistant MICs. There were no patients with <span class="Italics">H. pylori </span> isolates who developed treatment emergent resistance to amoxicillin.</p>
<p><span class="Italics">Susceptibility Test for Helicobacter pylori: </span>For susceptibility testing information about <span class="Italics">Helicobacter pylori</span>, see Microbiology section in prescribing information for clarithromycin and amoxicillin.</p>
<p><span class="Italics">Effects on Gastrointestinal Microbial Ecology:</span> Decreased gastric acidity due to any means, including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> and <span class="Italics">Campylobacter</span> and possibly <span class="Italics">Clostridium difficile</span> in hospitalized patients.</p>
<p>
 
</p>
<br><p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">7</a></dt>
<dd>Gastric pH was measured over a 24-hour period</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">8</a></dt>
<dd>p&lt; 0.01 NEXIUM 40 mg vs. NEXIUM 20 mg</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">9</a></dt>
<dd>Values represent the geometric mean, except the T</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">10</a></dt>
<dd></dd>
<dt><a name="footnote-11" href="#footnote-reference-11">11</a></dt>
<dd></dd>
<dt><a name="footnote-12" href="#footnote-reference-12">12</a></dt>
<dd>Geometric mean;</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">13</a></dt>
<dd>arithmetic mean</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">14</a></dt>
<dd>Duration of treatment for 12 to 17 year olds and adults were 8 days and 5 days, respectively. Data were obtained from two independent studies.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">15</a></dt>
<dd>Includes only patients with pretreatment and post-treatment clarithromycin susceptibility test results</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">16</a></dt>
<dd>Susceptible (S) MIC ≤ 0.25 mcg/mL, Intermediate (I) MIC = 0.5 mcg/mL, Resistant (R) MIC ≥ 1.0 mcg/mL </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>The carcinogenic potential of NEXIUM was assessed using studies of omeprazole, of which esomeprazole is an enantiomer. In two 24-month oral carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44, and 141 mg/kg/day (about 0.7 to 57 times the human dose of 20 mg/day expressed on a body surface area basis) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole.  Gastric carcinoids seldom occur in the untreated rat.  In addition, ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was present in all treated groups of both sexes.  In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (about 5.6 times the human dose on a body surface area basis) for 1 year, then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was observed at the end of 1 year (94% treated vs. 10% controls). By the second year the difference between treated and control rats was much smaller (46% vs. 26%) but still showed more <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for 2 years. For this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. A 78-week mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive.</p>
<p>Esomeprazole was negative in the Ames mutation test, in the <span class="Italics">in vivo</span> rat bone marrow cell chromosome aberration test, and the <span class="Italics">in vivo</span> mouse micronucleus test.  Esomeprazole, however, was positive in the <span class="Italics">in vitro</span> human lymphocyte chromosome aberration test. Omeprazole was positive in the <span class="Italics">in vitro </span>human lymphocyte chromosome aberration test, the <span class="Italics">in vivo</span> mouse bone marrow cell chromosome aberration test, and the <span class="Italics">in vivo</span> mouse micronucleus test. </p>
<p>The potential effects of esomeprazole on fertility and reproductive performance were assessed using omeprazole studies.  Omeprazole at oral doses up to 138 mg/kg/day in rats (about 56 times the human dose on a body surface area basis) was found to have no effect on reproductive performance of parental animals.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="Italics">Reproductive Toxicology Studies</span></p>
<p>Reproductive studies have been performed in rats at oral doses up to 280 mg/kg/day (about 57 times the human dose on a body surface area basis) and in rabbits at oral doses up to 86 mg/kg/day (about 35 times the human dose on a body surface area basis) and have revealed no evidence of impaired fertility or harm to the fetus due to esomeprazole.  </p>
<p>Reproductive studies conducted with omeprazole in rats at oral doses up to 138 mg/kg/day (about 56 times the human dose on a body surface area basis) and in rabbits at doses up to 69 mg/kg/day (about 56 times the human dose on a body surface area basis)  did not disclose any evidence for a teratogenic potential of omeprazole. In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (about 5.5 to 56 times the human dose on a body surface area basis) produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy disruptions. In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138.0 mg/kg/day (about 5.6 to 56 times the human dose on a body surface area basis).</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>The healing rates of NEXIUM 40 mg, NEXIUM 20 mg, and omeprazole 20 mg (the approved dose for this indication) were evaluated in patients with endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> in four multicenter, double-blind, randomized studies. The healing rates at Weeks 4 and 8 were evaluated and are shown in the Table 9:</p>
<a name="_RefID0E2QBI"></a><table>
<caption><span>Table 9: <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Healing Rate (Life-Table Analysis)</span></caption>
<col span="1" width="8%">
<col span="1" width="16%">
<col span="1" width="20%">
<col span="1" width="10%">
<col span="1" width="10%">
<col span="1" width="21%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"> Study</p></td>
<td><p class="First">No. of Patients</p></td>
<td><p class="First"> Treatment Groups</p></td>
<td><p class="First"> Week 4</p></td>
<td><p class="First"> Week 8</p></td>
<td><p class="First">Significance Level <a href="#footnote-1">*</a></p></td>
</tr>
<tr>
<td><p class="First">1</p></td>
<td><p class="First">588</p></td>
<td><p class="First">NEXIUM 20 mg</p></td>
<td><p class="First">68.7%</p></td>
<td><p class="First">90.6%</p></td>
<td><p class="First">N.S.<a href="#footnote-2">†</a></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">588</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">69.5%</p></td>
<td><p class="First">88.3%</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">2</p></td>
<td><p class="First">654</p></td>
<td><p class="First">NEXIUM 40 mg</p></td>
<td><p class="First">75.9%</p></td>
<td><p class="First">94.1%</p></td>
<td><p class="First">p &lt; 0.001</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">656</p></td>
<td><p class="First">NEXIUM 20 mg</p></td>
<td><p class="First">70.5%</p></td>
<td><p class="First">89.9%</p></td>
<td><p class="First">p &lt; 0.05</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">650</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">64.7%</p></td>
<td><p class="First">86.9%</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">3</p></td>
<td><p class="First">576</p></td>
<td><p class="First">NEXIUM 40 mg</p></td>
<td><p class="First">71.5%</p></td>
<td><p class="First">92.2%</p></td>
<td><p class="First">N.S.<a href="#footnote-18" class="Sup">18</a></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">572</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">68.6%</p></td>
<td><p class="First">89.8%</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">4</p></td>
<td><p class="First">1216</p></td>
<td><p class="First">NEXIUM 40 mg</p></td>
<td><p class="First">81.7%</p></td>
<td><p class="First">93.7%</p></td>
<td><p class="First">p &lt; 0.001</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">1209</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">68.7%</p></td>
<td><p class="First">84.2%</p></td>
<td></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>In these same studies of patients with <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, sustained <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> resolution and time to sustained <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> resolution were evaluated and are shown in the Table 10:</p>
<a name="_RefID0EHZBI"></a><table>
<caption><span>Table 10: Sustained Resolution<a href="#footnote-3">*</a> of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> (<span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> Patients)</span></caption>
<col span="1" width="8%">
<col span="1" width="16%">
<col span="1" width="20%">
<col span="1" width="23%">
<col span="1" width="23%">
<col span="1" width="21%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td></td>
<td></td>
<td><p class="First">Cumulative Percent<a href="#footnote-4">†</a> with Sustained Resolution</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Study</p></td>
<td><p class="First">No. of Patients</p></td>
<td><p class="First">Treatment Groups</p></td>
<td><p class="First">Day 14</p></td>
<td><p class="First">Day 28</p></td>
<td><p class="First">Significance Level <a href="#footnote-5">‡</a></p></td>
</tr>
<tr>
<td><p class="First">1</p></td>
<td><p class="First">573</p></td>
<td><p class="First">NEXIUM 20 mg</p></td>
<td><p class="First">64.3%</p></td>
<td><p class="First">72.7%</p></td>
<td><p class="First">N.S.<a href="#footnote-6">§</a></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">555</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">64.1%</p></td>
<td><p class="First">70.9%</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">2</p></td>
<td><p class="First">621</p></td>
<td><p class="First">NEXIUM 40 mg</p></td>
<td><p class="First">64.8%</p></td>
<td><p class="First">74.2%</p></td>
<td><p class="First">p &lt;0.001</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">620</p></td>
<td><p class="First">NEXIUM 20 mg</p></td>
<td><p class="First">62.9%</p></td>
<td><p class="First">70.1%</p></td>
<td><p class="First">N.S.<a href="#footnote-22" class="Sup">22</a></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">626</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">56.5%</p></td>
<td><p class="First">66.6%</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">3</p></td>
<td><p class="First">568</p></td>
<td><p class="First">NEXIUM 40 mg</p></td>
<td><p class="First">65.4%</p></td>
<td><p class="First">73.9%</p></td>
<td><p class="First">N.S.<a href="#footnote-22" class="Sup">22</a></p></td>
</tr>
<tr>
<td></td>
<td><p class="First">551</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">65.5%</p></td>
<td><p class="First">73.1%</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">4</p></td>
<td><p class="First">1187</p></td>
<td><p class="First">NEXIUM 40 mg</p></td>
<td><p class="First">67.6%</p></td>
<td><p class="First">75.1%</p></td>
<td><p class="First">p &lt;0.001</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">1188</p></td>
<td><p class="First">Omeprazole 20 mg</p></td>
<td><p class="First">62.5%</p></td>
<td><p class="First">70.8%</p></td>
<td></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>In these four studies, the range of median days to the start of sustained resolution (defined as 7 consecutive days with no <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>) was 5 days for NEXIUM 40 mg, 7 to 8 days for NEXIUM 20 mg and 7 to 9 days for omeprazole 20 mg.</p>
<p>There are no comparisons of 40 mg of NEXIUM with 40 mg of omeprazole in clinical trials assessing either healing or symptomatic relief of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>.</p>
<p><span class="Italics">Long-Term Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </span></p>
<p>Two multicenter, randomized, double-blind placebo-controlled 4-arm trials were conducted in patients with endoscopically confirmed, healed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> to evaluate NEXIUM 40 mg (n=174), 20 mg (n=180), 10 mg (n=168) or placebo (n=171) once daily over six months of treatment. </p>
<p>No additional clinical benefit was seen with NEXIUM 40 mg over NEXIUM 20 mg. </p>
<p>The percentages of patients that maintained healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> at the various time points are shown in the Figures 2 and 3:</p>
<p><span class="Bold">Figure 2: Maintenance of Healing Rates by Month (Study 177)</span></p>
<div class="Figure"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b533b80b-2e68-4c5c-aaba-159d96a1b2f0&amp;name=MM2.jpg"></div>
<p>s= scheduled visit</p>
<p><span class="Bold">Figure 3: Maintenance of Healing Rates by Month (Study 178)</span></p>
<div class="Figure"><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b533b80b-2e68-4c5c-aaba-159d96a1b2f0&amp;name=MM3.jpg"></div>
<p>s= scheduled visit</p>
<p>Patients remained in remission significantly longer and the number of recurrences of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> was significantly less in patients treated with NEXIUM compared to placebo. </p>
<p>In both studies, the proportion of patients on NEXIUM who remained in remission and were free of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms was well differentiated from placebo.</p>
<p>In a third multicenter open label study of 808 patients treated for 12 months with NEXIUM 40 mg, the percentage of patients that maintained healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> was 93.7% for six months and 89.4% for one year.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Two multicenter, randomized, double-blind, placebo-controlled studies were conducted in a total of 717 patients comparing four weeks of treatment with NEXIUM 20 mg or 40 mg once daily versus placebo for resolution of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms. Patients had ≥ 6-month history of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> episodes, no <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> by endoscopy, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> on at least four of the seven days immediately preceding randomization.</p>
<p>The percentage of patients that were symptom-free of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> was significantly higher in the NEXIUM groups compared to placebo at all follow-up visits (Weeks 1, 2, and 4). </p>
<p>No additional clinical benefit was seen with NEXIUM 40 mg over NEXIUM 20 mg. </p>
<p>The percent of patients symptom-free of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> by day are shown in the Figures 4 and 5:</p>
<p><span class="Bold">Figure 4: Percent of Patients Symptom-Free of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> by Day (Study 225)</span></p>
<div class="Figure"><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b533b80b-2e68-4c5c-aaba-159d96a1b2f0&amp;name=MM4.jpg"></div>
<p><span class="Bold">Figure 5: Percent of Patients Symptom-Free of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> by Day (Study 226)</span></p>
<div class="Figure"><img alt="MM5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b533b80b-2e68-4c5c-aaba-159d96a1b2f0&amp;name=MM5.jpg"></div>
<p>In three European symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> trials, NEXIUM 20 mg and 40 mg and omeprazole 20 mg were evaluated. No significant treatment related differences were seen.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="Italics">1 to 11 Years of Age</span></p>
<p>In a multicenter, parallel-group study, 109 pediatric patients with a history of endoscopically-proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (1 to 11 years of age; 53 female; 89 Caucasian, 19 Black, 1 Other) were treated with NEXIUM once daily for up to 8 weeks to evaluate safety and tolerability. Dosing by patient weight was as follows:</p> weight &lt; 20 kg: once daily treatment with NEXIUM 5 mg or 10 mg   weight ≥ 20 kg: once daily treatment with NEXIUM 10 mg or 20 mg  <p>Patients were endoscopically characterized as to the presence or absence of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>.  </p>
<p>Of the 109 patients, 53 had <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> at baseline (51 had mild, 1 moderate, and 1 severe <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>). Although most of the patients who had a follow up endoscopy at the end of 8 weeks of treatment healed, spontaneous healing cannot be ruled out because these patients had low grade <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> prior to treatment, and the trial did not include a concomitant control.</p>
<p><span class="Italics">12 to 17 Years of Age </span></p>
<p>In a multicenter, randomized, double-blind, parallel-group study, 149 adolescent patients (12 to 17 years of age; 89 female; 124 Caucasian, 15 Black, 10 Other) with clinically diagnosed <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were treated with either NEXIUM 20 mg or NEXIUM 40 mg once daily for up to 8 weeks to evaluate safety and tolerability.  Patients were not endoscopically characterized as to the presence or absence of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Two multicenter, double-blind, placebo-controlled studies were conducted in patients at risk of developing gastric and/or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> associated with continuous use of non-selective and COX-2 selective NSAIDs.  A total of 1429 patients were randomized across the 2 studies.  Patients ranged in age from 19 to 89 (median age 66.0 years) with 70.7% female, 29.3% male, 82.9% Caucasian, 5.5% Black, 3.7% Asian, and 8.0% Others.  At baseline, the patients in these studies were endoscopically confirmed not to have <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> but were determined to be at risk for <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> occurrence due to their age (≥60 years) and/or history of a documented gastric or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> within the past 5 years.  Patients receiving NSAIDs and treated with NEXIUM 20 mg or 40 mg once-a-day experienced significant reduction in <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> occurrences relative to placebo treatment at 26 weeks.  See Table 11. No additional benefit was seen with NEXIUM 40 mg over NEXIUM 20 mg. These studies did not demonstrate significant reduction in the development of NSAID-associated <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> due to the low incidence.</p>
<a name="_RefID0ESGCI"></a><table>
<caption><span> Table 11: Cumulative percentage of patients without <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> at 26 weeks:</span></caption>
<col span="1" width="8%">
<col span="1" width="16%">
<col span="1" width="18%">
<col span="1" width="44%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Study</p></td>
<td><p class="First">No. of Patients</p></td>
<td><p class="First">Treatment Group</p></td>
<td><p class="First">% of Patients Remaining <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> Free<a href="#footnote-1">*</a></p></td>
</tr>
<tr>
<td><p class="First">1</p></td>
<td>
<p class="First">191</p>
<p>194</p>
<p>184</p>
</td>
<td>
<p class="First">NEXIUM 20 mg</p>
<p>NEXIUM 40 mg</p>
<p>Placebo</p>
</td>
<td>
<p class="First">95.4</p>
<p>96.7</p>
<p>88.2</p>
</td>
</tr>
<tr>
<td><p class="First">2</p></td>
<td>
<p class="First">267</p>
<p>271</p>
<p>257</p>
</td>
<td>
<p class="First">NEXIUM 20 mg</p>
<p>NEXIUM 40 mg</p>
<p>Placebo</p>
</td>
<td>
<p class="First">94.7</p>
<p>95.3</p>
<p>83.3</p>
</td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="Italics">Triple Therapy (NEXIUM/amoxicillin/clarithromycin):</span> Two multicenter, randomized, double-blind studies were conducted using a 10 day treatment regimen. The first study (191) compared NEXIUM 40 mg once daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily to NEXIUM 40 mg once daily plus clarithromycin 500 mg twice daily. The second study (193) compared NEXIUM 40 mg once daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily to NEXIUM 40 mg once daily. <span class="Italics">H. pylori</span> eradication rates, defined as at least two negative tests and no positive tests from CLOtest<span class="Sup">®</span>, histology and/or culture, at 4 weeks post-therapy were significantly higher in the NEXIUM plus amoxicillin and clarithromycin group than in the NEXIUM plus clarithromycin or NEXIUM alone group. The results are shown in Table 12:</p>
<a name="_RefID0EYJCI"></a><table>
<caption><span>Table 12: H. pylori Eradication Rates at 4 Weeks after 10 Day Treatment Regimen % of Patients Cured [95% Confidence Interval] (Number of Patients)</span></caption>
<col span="1" width="8%">
<col span="1" width="45%">
<col span="1" width="15%">
<col span="1" width="17%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Study</p></td>
<td><p class="First">Treatment Group</p></td>
<td><p class="First">Per-Protocol<a href="#footnote-1">*</a></p></td>
<td><p class="First">Intent-to-Treat<a href="#footnote-2">†</a></p></td>
</tr>
<tr>
<td><p class="First">191</p></td>
<td><p class="First">NEXIUM plus amoxicillin and clarithromycin </p></td>
<td>
<p class="First">84%<a href="#footnote-3">‡</a></p>
<p>[78, 89]</p>
<p>(n=196)</p>
</td>
<td>
<p class="First">77%<a href="#footnote-26" class="Sup">26</a></p>
<p>[71, 82]</p>
<p>(n=233)</p>
</td>
</tr>
<tr>
<td></td>
<td><p class="First">NEXIUM plus clarithromycin</p></td>
<td>
<p class="First">55%</p>
<p>[48, 62]</p>
<p>(n=187)</p>
</td>
<td>
<p class="First">52%</p>
<p>[45, 59]</p>
<p>(n=215)</p>
</td>
</tr>
<tr>
<td><p class="First">193</p></td>
<td><p class="First">NEXIUM plus amoxicillin and clarithromycin </p></td>
<td>
<p class="First">85%<a href="#footnote-4">§</a></p>
<p>[74, 93]</p>
<p>(n=67)</p>
</td>
<td>
<p class="First">78%<a href="#footnote-27" class="Sup">27</a></p>
<p>[67, 87]</p>
<p>(n=74)</p>
</td>
</tr>
<tr>
<td></td>
<td><p class="First">NEXIUM</p></td>
<td>
<p class="First">5%</p>
<p>[0, 23]</p>
<p>(n=22)</p>
</td>
<td>
<p class="First">4%</p>
<p>[0, 21]</p>
<p>(n=24)</p>
</td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>The percentage of patients with a healed baseline <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> by 4 weeks after the 10 day treatment regimen in the NEXIUM plus amoxicillin and clarithromycin group was 75% (n=156) and 57% (n=60) respectively, in the 191 and 193 studies (per-protocol analysis). </p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>In a multicenter, open-label dose-escalation study of 21 patients (15 males and 6 females, 18 Caucasian and 3 Black, mean age of 55.5 years) with pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome, NEXIUM significantly inhibited gastric acid secretion.  Initial dose was 40 mg twice daily in 19/21 patients and 80 mg twice daily in 2/21 patients. Total daily doses ranging from 80 mg to 240 mg for 12 months maintained gastric acid output below the target levels of 10 mEq/h in patients without prior gastric acid-reducing surgery and below 5 mEq/hr in patients with prior gastric acid-reducing surgery.  At the Month 12 final visit, 18/20 (90%) patients had Basal Acid Output (BAO) under satisfactory control (median BAO = 0.17 mmol/hr). Of the 18 patients evaluated with a starting dose of 40 mg twice daily, 13 (72%) had their BAO controlled with the original dosing regimen at the final visit. See Table 13.</p>
<a name="_RefID0EWOCI"></a><table>
<caption><span>Table 13: Adequate Acid Suppression at Final Visit by Dose Regimen</span></caption>
<col span="1" width="36%">
<col span="1" width="57%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">NEXIUM dose at the Month 12 visit</p></td>
<td><p class="First">BAO under adequate control at the Month 12 visit (N=20)<a href="#footnote-1">*</a></p></td>
</tr>
<tr>
<td><p class="First">40 mg twice daily</p></td>
<td><p class="First">13/15</p></td>
</tr>
<tr>
<td><p class="First">80 mg twice daily</p></td>
<td><p class="First">4/4</p></td>
</tr>
<tr>
<td><p class="First">80 mg three times daily</p></td>
<td><p class="First">1/1</p></td>
</tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p>
 
</p>
<br><p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">17</a></dt>
<dd>log-rank test vs. omeprazole 20 mg</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">18</a></dt>
<dd>N.S. = not significant (p &gt; 0.05)</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">19</a></dt>
<dd>Defined as 7 consecutive days with no <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> reported in daily patient diary.</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">20</a></dt>
<dd>Defined as the cumulative proportion of patients who have reached the start of sustained resolution</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">21</a></dt>
<dd>log-rank test vs. omeprazole 20 mg</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">22</a></dt>
<dd>N.S. = not significant (p &gt; 0.05)</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">23</a></dt>
<dd>%= Life Table Estimate. Significant difference from placebo (p&lt;0.01).</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">24</a></dt>
<dd>Patients were included in the analysis if they had H. pylori <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> documented at baseline, had at least one endoscopically verified <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> ≥ 0.5 cm in diameter at baseline or had a documented history of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease within the past 5 years, and were not protocol violators.  Patients who dropped out of the study due to an adverse reaction related to the study drug were included in the analysis as not H. pylori eradicated.</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">25</a></dt>
<dd>Patients were included in the analysis if they had documented H. pylori <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline, had at least one documented <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> at baseline, or had a documented history of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease, and took at least one dose of study medication.  All dropouts were included as not H. pylori eradicated.</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">26</a></dt>
<dd> p &lt; 0.05 compared to NEXIUM plus clarithromycin.</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">27</a></dt>
<dd> p &lt; 0.05 compared to NEXIUM alone.</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">28</a></dt>
<dd>One patient was not evaluated.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>NEXIUM Delayed-Release Capsules, 20 mg, are opaque, hard gelatin, amethyst colored capsules with two radial bars in yellow on the cap and NEXIUM 20 mg in yellow on the body.  They are supplied as follows:</p>
<p>NDC 0186-5020-31 unit of use bottles of 30</p>
<p>NDC 0186-5022-28 unit dose packages of 100</p>
<p>NDC 0186-5020-54 bottles of 90</p>
<p>NDC 0186-5020-82 bottles of 1000</p>
<p>NEXIUM Delayed-Release Capsules, 40 mg, are opaque, hard gelatin, amethyst colored capsules with three radial bars in yellow on the cap and NEXIUM 40 mg in yellow on the body.  They are supplied as follows:</p>
<p>NDC 0186-5040-31 unit of use bottles of 30</p>
<p>NDC 0186-5042-28 unit dose packages of 100</p>
<p>NDC 0186-5040-54 bottles of 90</p>
<p>NDC 0186-5040-82 bottles of 1000</p>
<p>NDC 0186-5040-35 unit of use bottles of 30 </p>
<p>NDC 0186-5042-25 unit dose packages of 100 </p>
<p>NDC 0186-5040-55 bottles of 90 </p>
<p>NDC 0186-5040-85 bottles of 1000</p>
<p>NEXIUM For Delayed-Release Oral Suspension is supplied as a unit dose packet containing a fine yellow powder, consisting of white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> brownish esomeprazole granules and <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow inactive granules. NEXIUM unit dose packets are supplied as follows:</p>
<p>NDC 0186-4025-01 unit dose packages of 30: 2.5 mg packets</p>
<p>NDC 0186-4050-01 unit dose packages of 30: 5 mg packets</p>
<p>NDC 0186-4010–01 unit dose packages of 30: 10 mg packets</p>
<p>NDC 0186-4020–01 unit dose packages of 30: 20 mg packets</p>
<p>NDC 0186-4040–01 unit dose packages of 30: 40 mg packets</p>
<p>Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature]. Keep NEXIUM Delayed-Release Capsules container tightly closed. Dispense in a tight container if the NEXIUM Delayed-Release Capsules product package is subdivided.</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p>“See FDA-Approved Medication Guide?</p>•Advise patients to let you know if they are taking, or begin taking, other medications, because NEXIUM can interfere with antiretroviral drugs and drugs that are affected by gastric pH changes [<span class="Italics">see <a href="#ID_5dccf20c-0eb6-45e2-a383-43b8c304402f">Drug Interactions (7.1)</a></span>].•Let patients know that antacids may be used while taking NEXIUM.•Advise patients to take NEXIUM at least one hour before a meal. •For patients who are prescribed NEXIUM Delayed-Release Capsules, advise them not to chew or crush the capsules.  •Advise patients that, if they open NEXIUM Delayed-Release Capsules to mix the granules with food, the granules should only be mixed with applesauce.  Use with other foods has not been evaluated and is not recommended.•For patients who are advised to open the NEXIUM Delayed-Release Capsules before taking them or who are prescribed NEXIUM For Delayed-Release Oral Suspension, instruct them in the proper technique for administration [<span class="Italics">see <a href="#williamsonbk1158841553901">Dosage and Administration (2)</a></span>] and tell them to follow the dosing instructions in the PATIENT INFORMATION insert included in the package. Instruct patients to rinse the syringe with water after each use.•For patients who are prescribed NEXIUM for Delayed-Release Oral Suspension and need to use more than one packet for their dose, instruct them regarding the correct amount of water to use when mixing their dose.<p>Advise patients to immediately report and seek care for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve.  This may be a sign of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [<span class="Italics">see </span><span class="Italics"><a href="#ID_a66ca398-faeb-4b37-a161-b14c9f9fbdd6">Warnings and Precautions (5.3</a>)</span>].</p>
<p>Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> as these may be signs of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> [<span class="Italics">see </span><span class="Italics"><a href="#ID_c805218f-6cd9-4228-b9ab-dfadd21f0587">Warnings and Precautions (5.6)</a></span>].</p>
<p>Distributed by: </p>
<p>AstraZeneca LP  </p>
<p>Wilmington, DE  19850  </p>
<p>NEXIUM and the color purple as applied to the capsule are registered trademarks of the AstraZeneca group of companies. </p>
<p>©AstraZeneca 2012</p>
<p>Rev. 11/2012</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-16"></a><p></p>
<h1>SPL MEDGUIDE</h1>
<a href="http://"></a><p class="First"></p>
<a href="http://"></a><p></p>
<p><span class="Bold">NEXIUM<span class="Sup">®</span> (nex-e-um) </span></p>
<p><span class="Bold">(esomeprazole magnesium) </span></p>
<p><span class="Bold">Delayed-Release Capsules</span></p>
<p><span class="Bold"></span></p>
<p><span class="Bold">NEXIUM<span class="Sup">®</span> (nex-e-um)</span></p>
<p><span class="Bold">(esomeprazole magnesium) </span></p>
<p><span class="Bold">For Delayed-Release <br>Oral Suspension</span></p>
<p>Read the Medication Guide that comes with NEXIUM before you start taking NEXIUM and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about NEXIUM?</span></p>
<p><span class="Bold">NEXIUM may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor. </span></p>
<p><span class="Bold">NEXIUM can cause serious side effects, including:</span></p>•<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span>. NEXIUM may increase your risk of getting severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. This <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be caused by an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">(Clostridium difficile)</span> in your intestines. <br>Call your doctor right away if you have watery stool, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> that does not go away.<br>•<span class="Bold">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></span>. People who take multiple daily doses of Proton Pump Inhibitor medicines for a long period of time (a year or longer) may have an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. You should take NEXIUM exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor about your risk of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> if you take NEXIUM.<br><br>NEXIUM can have other serious side effects.  See “<span class="Bold">What are the possible side effects of NEXIUM</span>??<p><span class="Bold">What is NEXIUM?</span></p>
<p>NEXIUM is a prescription medicine called a proton pump inhibitor (PPI). NEXIUM reduces the amount of acid in your stomach.</p>
<p>NEXIUM is used in adults:</p>•for 4 to 8 weeks to treat the symptoms of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>). NEXIUM may also be prescribed to heal acid-related damage to the lining of the esophagus (<span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>), and to help continue this healing. •<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> happens when acid in your stomach backs up into the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste, or burping.•for up to 6 months to reduce the risk of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span> in some people taking <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines called non-steroidal anti-inflammatory drugs (NSAIDs).•to treat patients with a stomach <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (Helicobacter pylori), along with the antibiotics amoxicillin and clarithromycin.•for the long-term treatment of conditions where your stomach makes too much acid, including Zollinger-Ellison Syndrome. Zollinger-Ellison Syndrome is a rare condition in which the stomach produces a more than normal amount of acid.<p>For children and adolescents 1 year to 17 years of age, NEXIUM may be prescribed for up to 8 weeks for short-term treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>.</p>
<p>In children ages 1 month to less than 1 year of age, NEXIUM is only used to treat <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> with acid-related damage to the esophagus (<span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>) for up to 6 weeks.</p>
<p>It is not known if NEXIUM is effective in children under 1 month of age.</p>
<p><span class="Bold">Who should not take NEXIUM?</span></p>
<p>Do not take NEXIUM if you:</p>•are allergic to esomeprazole magnesium or any of the ingredients in NEXIUM. See the end of this Medication Guide for a complete list of ingredients in NEXIUM.•are allergic to any other Proton Pump Inhibitor (PPI) medicine. <p><span class="Bold">What should I tell my doctor before taking NEXIUM?</span></p>
<p><span class="Bold">Before you take NEXIUM, tell your doctor if you:</span></p>•have been told that you have low magnesium levels in your blood•have liver problems•are pregnant or plan to become pregnant. It is not known if NEXIUM can harm your unborn baby.•are breastfeeding or planning to breastfeed. It is not known if NEXIUM passes into your breastmilk. You and your doctor should decide if you will take NEXIUM or breastfeed.  You should not do both. Talk to your doctor about the best way to feed your baby if you take NEXIUM.<p><span class="Bold">Tell your doctor about all of the medicines you take</span>, including prescription and non-prescription drugs, vitamins and herbal supplements. NEXIUM may affect how other medicines work, and other medicines may affect how NEXIUM works. </p>•Especially tell your doctor if you take:•warfarin (Coumadin, Jantoven)•ketoconazole (Nizoral)•voriconazole (Vfend)•atazanavir (Reyataz)•nelfinavir (Viracept)•saquinavir (Fortovase)•products that contain iron •digoxin (Lanoxin)•St.John’s Wort (Hypericum perforatum)•Rifampin (Rimactane, Rifater, Rifamate)•cilostazol (Pletal) •diazepam (Valium) •tacrolimus (Prograf)•erlotinib (Tarceva)•methotrexate•clopidogrel (Plavix)<p><span class="Bold">How should I take NEXIUM?</span></p>•Take NEXIUM exactly as prescribed by your doctor. •Do not change your dose or stop NEXIUM without talking to your doctor.•Take NEXIUM at least 1 hour before a meal.•Swallow NEXIUM capsules whole. <span class="Bold">Never chew or crush NEXIUM.</span>•If you have difficulty swallowing NEXIUM capsules, you may open the capsule and empty the contents into a tablespoon of applesauce. Do not crush or chew the granules. Be sure to swallow the applesauce right away. Do not store it for later use.•If you forget to take a dose of NEXIUM, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose on time. Do not take a double dose to make up for a missed dose. •If you take too much NEXIUM, call your doctor or local poison control center right away, or go to the nearest hospital emergency room. •See the “Instructions for Use? at the end of this Medication Guide for instructions how to take NEXIUM For Delayed-Release Oral Suspension, and how to mix and give NEXIUM Delayed-Release Capsules and NEXIUM For Delayed-Release Oral Suspension, through a nasogastric tube or gastric tube.<p><span class="Bold">What are the possible side effects of NEXIUM?</span></p>
<p><span class="Bold">NEXIUM can cause serious side effects, including: </span></p>•See “<span class="Bold">What is the most important information I should know about NEXIUM??</span>•<span class="Bold">Chronic (lasting a long time) <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the stomach lining (<span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic Gastritis</span>)</span>. Using NEXIUM for a long period of time may increase the risk of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> to your stomach lining.  You may or may not have symptoms. Tell your doctor if you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.•<span class="Bold">Low magnesium levels in your body.</span>  This problem can be serious. Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment.  You may or may not have symptoms of low magnesium. <br>Tell you doctor right away if you have any of these symptoms:•seizures•dizziness•abnormal or fast heart beat•jitteriness•jerking movements or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>)•muscle weakness•<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the hands and feet•<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> or muscle aches•spasm of the voice box<p>Your doctor may check the level of magnesium in your body before you start taking NEXIUM or during treatment if you will be taking NEXIUM for a long period of time.</p>
<p>The most common side effects with NEXIUM may include:</p>•headache•<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> •<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> •gas •abdominal pain•constipation•dry mouth•<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span><p>Other side effects:</p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span>. Tell your doctor if you get any of the following symptoms with NEXIUM:</p>•rash•face swelling•throat tightness•<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span><p>Your doctor may stop NEXIUM if these symptoms happen.</p>
<p>Tell your doctor if you have any side effects that bother you or that do not go away. These are not all the possible side effects with NEXIUM. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store NEXIUM?</span></p>•Store NEXIUM at room temperature between 68°F to 77°F (20°C to 25°C).•Keep the container of NEXIUM closed tightly.<p><span class="Bold">Keep NEXIUM and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about NEXIUM</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NEXIUM for a condition for which it was not prescribed. Do not give NEXIUM to other people, even if they have the same symptoms you have. It may harm them. </p>
<p>This Medication Guide summarizes the most important information about NEXIUM. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about NEXIUM that is written for health professionals. </p>
<p>For more information, go to www.purplepill.com or call 1-800-463-9486.</p>
<p><span class="Bold">What are the ingredients in NEXIUM?</span></p>
<p>Active ingredient: esomeprazole magnesium trihydrate</p>
<p><span class="Bold">Inactive ingredients in NEXIUM Delayed-Release Capsules (including the capsule shells):</span> glyceryl monostearate 40-55, hydroxypropyl cellulose, hypromellose, magnesium stearate, methacrylic acid copolymer type C, polysorbate 80, sugar spheres, talc, triethyl citrate, gelatin, FD&amp;C Blue #1, FD&amp;C Red #40, D&amp;C Red #28, titanium dioxide, shellac, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, sodium hydroxide, polyvinyl pyrrolidone, and D&amp;C Yellow #10. </p>
<p><span class="Bold">Inactive granules in NEXIUM For Delayed-Release Oral Suspension:</span> dextrose, xanthan gum, crospovidone, citric acid, iron oxide, and hydroxypropyl cellulose.</p>
<p><span class="Bold">Instructions for Use</span></p>
<p>For instructions on taking Delayed-Release Capsules, see the section of this leaflet called “<span class="Bold">How should I take NEXIUM?</span>? </p>
<p>Take NEXIUM For Delayed-Release Oral Suspension as follows:</p>•NEXIUM For Delayed-Release Oral Suspension comes in foil packets containing 2.5 mg, 5 mg, 10 mg, 20 mg, or 40 mg strengths.•You should use an oral syringe to measure the amount of water needed to mix your dose. Ask your pharmacist for an oral syringe.•If your prescribed dose is 2.5 mg or 5 mg, add 5 mL of water to a container, then add the contents of a foil packet containing the dose prescribed by your doctor.•If your prescribed dose is 10 mg, 20 mg, or 40 mg, add 15 mL of water to a container, then add the contents of a foil packet containing the dose prescribed by your doctor. •If you or your child are instructed to use more than one foil packet for the prescribed dose, follow the mixing instructions provided by your pharmacist or doctor. •Stir.•Leave 2 to 3 minutes to thicken.•Stir and take dose within 30 minutes. If not used within 30 minutes, throw away this dose and mix a new dose. •If any medicine remains after drinking, add more water, stir, and take dose right away.•For young children, you can give the dose with an oral syringe. Rinse the oral syringe with water after each use.<p>NEXIUM Delayed-Release Capsules and NEXIUM For Delayed-Release Oral Suspension may be given through a nasogastric tube (NG tube) or gastric tube, as prescribed by your doctor. Follow the instructions below:</p>
<p>NEXIUM Delayed-Release Capsules:</p>•Open the capsule and empty the granules into a 60 mL catheter tipped syringe. Mix with 50 mL of water. Use only a catheter tipped syringe to give NEXIUM through a NG tube.•Replace the plunger and shake the syringe well for 15 seconds. Hold the syringe with the tip up and check for granules in the tip.•Give the medicine right away.•Do not give the granules if they have dissolved or have broken into pieces.•Attach the syringe to the NG tube. Give the medicine in the syringe through the NG tube into the stomach. •After giving the granules, flush the NG tube with more water.<p>NEXIUM For Delayed-Release Oral Suspension:</p>•NEXIUM For Delayed-Release Oral Suspension comes in foil packets containing 2.5 mg, 5 mg, 10 mg, 20 mg, or 40 mg strengths.•Use only a catheter tipped syringe to give NEXIUM through a NG tube or gastric tube•If your prescribed dose is 2.5 mg or 5 mg, add 5 mL of water to a catheter tipped syringe, then add the contents of a foil packet containing the dose prescribed by your doctor.•If your prescribed dose is 10 mg, 20 mg, or 40 mg, add 15 mL of water to a catheter tipped syringe, then add the contents of a foil packet containing the dose prescribed by your doctor. •Shake the syringe right away and then leave it for 2 to 3 minutes to thicken.•Shake the syringe and give the medicine through the NG or gastric tube (French size 6 or larger) into the stomach within 30 minutes. •Refill the syringe with the same amount of water (either 5 mL or 15 mL of water depending on your dose).•Shake the syringe and flush any remaining medicine from the NG tube or gastric tube into the stomach.<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>Issued November 2012</p>
<p>NEXIUM is a registered trademark of the AstraZeneca group of companies.</p>
<p>©2012 AstraZeneca Pharmaceuticals LP. All rights reserved</p>
<p>
 
</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
    DRUG: NEXIUM <br>GENERIC: Esomeprazole magnesium<br>DOSAGE: CAPSULE, DELAYED RELEASE<br>ADMINSTRATION: ORAL<br>NDC: 52125-067-02<br>STRENGTH:20 mg<br>COLOR: purple<br>SHAPE: CAPSULE<br>SCORE: No score<br>SIZE: 14 mm<br>IMPRINT: 30<br>QTY: 30<br><br><div class="Figure"><img alt="MM6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b533b80b-2e68-4c5c-aaba-159d96a1b2f0&amp;name=MM6.jpg"></div>
<div class="Figure"><img alt="MM7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b533b80b-2e68-4c5c-aaba-159d96a1b2f0&amp;name=MM7.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEXIUM 		
					</strong><br><span class="contentTableReg">esomeprazole magnesium capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-067(NDC:0186-5020)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESOMEPRAZOLE MAGNESIUM</strong> (ESOMEPRAZOLE) </td>
<td class="formItem">ESOMEPRAZOLE</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN HYDROLYSATE (PORCINE SKIN, MW 3000)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL, X-RAY EXPOSED (1000 RAD)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM SORBATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER BUFFALO, COOKED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS DEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">purple</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE, DELAYED RELEASE) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NEXIUM20mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-067-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021153</td>
<td class="formItem">02/22/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>484175fd-dfac-4233-8645-1c56edb103db</div>
<div>Set id: b533b80b-2e68-4c5c-aaba-159d96a1b2f0</div>
<div>Version: 4</div>
<div>Effective Time: 20130222</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
